接受葡萄糖皮质类药物治疗的狼性炎患者的特征和预后:使用日本索赔数据库进行描述性研究
Kenichi Hiraga1, Izumi Sato1,2, Koji Kawakami1
1Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Current medical research and opinion
|November 14, 2023
概括
在接受较高初始剂量的葡萄糖皮质激素的患者中,狼性炎的治疗加剧更为频繁. 这项研究分析了2010-2019年日本索赔数据,以评估治疗模式.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 狼性炎 (LN) 是系统性红斑狼的严重并发症,需要有效的治疗策略.
- 葡萄皮质类药物是LN管理的基石,但最佳剂量和治疗强化方案仍然是研究领域.
- 在现实环境中了解治疗模式对于改善患者的治疗结果至关重要.
研究的目的:
- 评估2010年至2019年期间日本狼性炎治疗的现状.
- 具体评估狼性炎患者治疗加剧的需要和速度.
- 分析初始葡萄糖皮质体剂量与治疗强化之间的关系.
主要方法:
- 一项描述性研究,利用从2010年到2019年的大规模日本索赔数据库.
- 纳入标准:成年狼性炎患者的初始普雷迪尼索隆相当剂量≥15毫克/天.
- 卡普兰-梅尔法被用来评估六组的治疗强化率,基于最初的葡萄糖皮质激素剂量.
主要成果:
- 总共分析了403名患者,平均初始葡萄糖皮质体剂量为每天30毫克的普雷迪尼索隆相当剂量.
- 观察到56次治疗强化,导致每1000人/年发生率为71.3.
- 与较低剂量组相比,较高初始葡萄糖皮质体剂量组的治疗强化率显著更高.
结论:
- 狼性炎患者的治疗强化率与较高的初始葡萄糖皮质激素剂量有关.
- 这些发现表明,初始剂量策略可能会影响后续治疗需求.
- 需要进一步的研究来阐明初始葡萄糖皮质醇剂量与狼性炎的长期预后之间的确切关系.
更多相关视频
相关概念视频
01:24Nephrotic Syndrome III : Nursing Management
17
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
17
01:26Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:28Chronic Kidney Disease III: Interprofessional Care
13
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
13
01:24Nephrotic Syndrome I : Introduction
8
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
8
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K